From: Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution
Characteristic | Stratification | # pts | % |
---|---|---|---|
Sex | Male | 77 | 90.6 |
Female | 8 | 9.4 | |
Primary tumor site | Tonsil | 37 | 43.5 |
Base of tongue | 46 | 54.1 | |
Pharyngeal wall | 2 | 2.4 | |
AJCC stage | I | 2 | 2.4 |
II | 7 | 8.2 | |
III | 8 | 9.4 | |
IV | 68 | 80.0 | |
Smoking at diagnosis | No | 67 | 78.8 |
Yes | 18 | 21.2 | |
Smoking during follow up | No | 73 | 85.9 |
Yes | 12 | 14.1 | |
PEG | No | 17 | 20.0 |
Yes | 68 | 80.0 | |
Px dose to PTV1 | 68.25 Gy | 5 | 5.9 |
70 Gy | 80 | 94.1 | |
Chemotherapy | Concomitant (Platin-based) | 63 | 74.1 |
Induction + Concomitant | 7 | 8.2 | |
Cetuximab | 5 | 5.9 | |
None | 10 | 11.8 |